Organ Lesions in Adults with Secondary Hemophagocytic Syndrome

Author:

Potapenko Vsevolod Gennadevich12,Klimovich A.V.1,Avdoshina D.D.3,Baikov V.V.2,Vinogradova N.V.3,Goloshchapov O.V.2,Doguzhieva E.V.3,Zinina E.E.4,Kachenya G.V.3,Krivolapov Yu.A.5,Karyagina E.V.6,Kulibaba T.G.7,Lapin S.V.2,Leenman E.E.5,Pavlyuchenko E.S.5,Potikhonova N.A.8,Pervakova M.Yu.2,Popova N.B.4,Rysev A.V.9,Ryabchikova V.V.1,Surkova E.A.2,Fedunyak I.P.3,Medvedeva N.V.1

Affiliation:

1. Municipal Clinical Hospital No. 31

2. IP Pavlov First Saint Petersburg State Medical University

3. SP Botkin Clinical Hospital for Infectious Diseases

4. Surgut District Clinical Hospital

5. II Mechnikov North-Western State Medical University

6. Municipal Hospital No. 15

7. Saint Petersburg State University

8. Russian Research Institute of Hematology and Transfusiology

9. II Dzhanelidze Saint Petersburg Research Institute of Emergency Medicine

Abstract

Background. Secondary hemophagocytic syndrome (SHPS) is a reaction of systemic hyperinflammation triggered by infectious, tumor, or autoimmune processes. With no immunosuppressive (modulating) therapy most patients die from multiple organ failure. Aim. To describe organ lesions characteristic of SHPS patients. Materials & Methods. The retrospective study included patients treated from June 2009 to June 2019. SHPS was diagnosed using HLH-2004 criteria and H-Score. The analysis focused on the incidence and character of lesions in lungs, central nervous system, liver, skin, and cardiovascular system. All patients with persistent fever received anti-infective treatment with broad-spectrum antibiotics in line with local hospital practice. Patients with collagenosis and tumors, which caused SHPS, received standard immunosuppressive and antitumor therapy, respectively. Results. The analysis covered the data of 91 patients (41 man and 50 women), median age was 58 years (range 2-90 years). SHPS was caused by hematological malignancies (n = 52; 57 %), infections (n = 11; 12 %), autoimmune diseases (n = 5; 6 %), and allogeneic hematopoietic stem cell transplantation (n = 13; 14 %). In 10 (11 %) patients no cause was identified. Immunosuppressive therapy was administered to 71 (78 %) patients. Overall survival was 27 % (median 15 days) with median follow-up for alive of 540 days (range from 7 days to 10 years). Clinically significant organ lesions were identified in 76 (83 %) patients. Most commonly SHPS was reported together with polyserositis, respiratory and hepatic disorders, and neurological symptoms from focal deficit to seizure status. Less often skin lesions (from macular rash to epidermolysis bullosa) and such cardiovascular disorders as arrhythmia and/or arterial hypotension were observed. The effective SHPS therapy resulted in restoration of organ functions. Conclusion. SHPS can cause respiratory disorders, polyserositis, different neurological disorders, cytopenia in patients with unexplained fever and cytolytic and/or cholestatic syndrome. Primary organ lesions as well as clinical and laboratory manifestations of SHPS may vary in different patients.

Publisher

Practical Medicine Publishing House

Subject

Oncology,Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3